Welcome to our dedicated page for Theravance Biopharma SEC filings (Ticker: TBPH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Theravance Biopharma's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Theravance Biopharma's regulatory disclosures and financial reporting.
Theravance Biopharma CEO Rick E. Winningham received an equity grant of 75,000 Ordinary Shares at no cost. The award was recorded as a grant or other acquisition on Ordinary Shares.
Following this grant, he directly holds 1,651,094 Ordinary Shares and also reports indirect holdings of 23,400 shares as custodian and 92,567 shares held by a trust.
Sawaf Aziz reported acquisition or exercise transactions in this Form 4 filing.
Theravance Biopharma, Inc. reported that its SVP & Chief Financial Officer, Aziz Sawaf, received a grant of 37,500 Ordinary Shares on April 1, 2026. The shares were awarded at a stated price of $0.00 per share, reflecting compensation rather than a market purchase.
Following this award, Mr. Sawaf directly holds 353,623 Ordinary Shares of Theravance Biopharma. This filing records a stock-based compensation grant to a senior executive, not an open-market buy or sell transaction.
Grimaud Brett A. reported acquisition or exercise transactions in this Form 4 filing.
Theravance Biopharma, Inc. executive Brett A. Grimaud, SVP, General Counsel and Secretary, received a grant of 37,500 Ordinary Shares on April 1, 2026. The shares were awarded at a stated price of $0.00 per share as compensation rather than a market purchase. Following this grant, his direct holdings increased to 371,949 Ordinary Shares, according to the filing.
Farnum Rhonda reported acquisition or exercise transactions in this Form 4 filing.
Theravance Biopharma, Inc. reported that SVP, Commercial & Medical Affairs Rhonda Farnum received a grant of 18,750 Ordinary Shares of the company on April 1, 2026. The shares were granted at a stated price of $0.00 per share as compensation rather than a market purchase.
Following this award, Farnum directly holds a total of 251,449 Ordinary Shares of Theravance Biopharma, Inc., reflecting an increase in her equity-based compensation stake in the company.
Theravance Biopharma, Inc. announced a settlement of patent litigation over its YUPELRI® (revefenacin) inhalation solution. Theravance and its partner Mylan granted Mankind Pharma a royalty-free, non-exclusive license to sell a generic YUPELRI in the U.S. starting on the Licensed Launch Date of April 23, 2039, subject to customary exceptions.
The agreement resolves all pending Hatch-Waxman patent disputes related to YUPELRI. The settlement will be reviewed by the U.S. Department of Justice and the Federal Trade Commission, as required for patent settlements involving branded and generic drug makers.
Weiss Asset Management and related entities filed Amendment No. 3 to their Schedule 13D on Theravance Biopharma, Inc. The filing reports beneficial ownership of 7,457,060 ordinary shares, representing 14.5% of Theravance’s outstanding shares, based on 51,492,924 shares outstanding as of February 28, 2026.
The filing notes that 4,628,074 shares, or 9.0% of the company, are held by BIP, and 2,828,986 shares, or 5.5%, are held by BGO. Weiss Asset Management LP serves as investment manager to both funds, and Andrew M. Weiss, through WAM GP LLC, has power to vote and dispose of these shares. The reporting persons state they have not effected any transactions in Theravance shares during the past 60 days.
Theravance Biopharma reports a pivotal shift in its business following mixed 2025 developments. YUPELRI® net sales rose 12% to $266.6 million, triggering a $25.0 million milestone from Viatris and reaching record annual sales and brand profitability.
The company sold its remaining TRELEGY® royalty interest to GSK for $225.0 million and received a $50.0 million TRELEGY milestone in 2026, while up to $100.0 million in additional TRELEGY milestones remain available. However, Phase 3 ampreloxetine (CYPRESS) failed its primary endpoint, leading to wind-down of that program.
In response, Theravance is implementing a restructuring that will wind down R&D, significantly reduce G&A, and is expected to cut operating expenses by about 60% versus 2025, delivering roughly $70 million in annualized savings from Q3 2026. A Strategic Review Committee is urgently evaluating alternatives, including a potential sale of the company, to maximize shareholder value.
Theravance Biopharma reported a sharp turnaround for 2025, with revenue rising to $107.5M from $64.4M and net income improving to $105.9M from a $56.4M loss in 2024. Q4 revenue was $45.9M and net income $61.0M.
YUPELRI® remained the core driver, with 2025 net sales of $266.6M (Viatris-reported) versus $238.6M in 2024. The company is winding down R&D, cutting G&A about 50%, and expects operating expenses to fall about 60% from 2025’s $111.1M, targeting $60–70M of annualized cash flow from Q3 2026.
A Board Strategic Review Committee of independent directors, advised by Lazard, is urgently evaluating alternatives, including a potential sale of the company, following the CYPRESS study not meeting its primary endpoint and the wind-down of the ampreloxetine program.
Theravance Biopharma, Inc. senior executive Rhonda Farnum, SVP, Commercial & Medical Affairs, sold a total of 31,067 ordinary shares of TBPH in open-market transactions on March 16, 2026, at prices ranging from $13.755 to $14.01. After these sales, she directly owns 232,699 ordinary shares of the company.